Kyle Bass challenges second Vimovo patent

09-06-2015

Kyle Bass challenges second Vimovo patent

retrorocket / Shutterstock.com

Hedge fund manager Kyle Bass has filed another petition for an inter partes review (IPR) of a patent covering Horizon Pharma’s arthritis drug Vimovo (naproxen/esomeprazole magnesium).


Kyle Bass, Vimovo, inter partes review, Coalition for Affordable Drugs, Horizon Pharma

LSIPR